ORGO
NASDAQ · Biotechnology
Organogenesis Holdings Inc
$0.84
-0.03 (-3.46%)
Financial Highlights (FY 2026)
Revenue
591.69M
Net Income
38.84M
Gross Margin
75.6%
Profit Margin
6.6%
Rev Growth
+7.8%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 75.6% | 75.6% | 62.1% | 62.1% |
| Operating Margin | 7.9% | 7.1% | 10.4% | 9.2% |
| Profit Margin | 6.6% | 6.2% | 9.2% | 10.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 591.69M | 549.09M | 163.70M | 183.70M |
| Gross Profit | 447.44M | 415.22M | 101.68M | 114.10M |
| Operating Income | 46.86M | 39.14M | 17.05M | 16.82M |
| Net Income | 38.84M | 32.44M | 15.03M | 18.71M |
| Gross Margin | 75.6% | 75.6% | 62.1% | 62.1% |
| Operating Margin | 7.9% | 7.1% | 10.4% | 9.2% |
| Profit Margin | 6.6% | 6.2% | 9.2% | 10.2% |
| Rev Growth | +7.8% | +7.8% | +17.3% | -10.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.79M | 2.79M | 23.91M | 23.00M |
| Total Equity | 54.57M | 54.57M | 148.92M | 172.86M |
| D/E Ratio | 0.05 | 0.05 | 0.16 | 0.13 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 62.89M | 55.44M | 20.76M | 25.89M |
| Free Cash Flow | — | — | 17.26M | 13.87M |